A Catalano1, A Gaudio2, N Morabito3, G Basile3, R M Agostino4, A Xourafa2, M Atteritano3, E Morini3, G Natale5, A Lasco3. 1. Department of Clinical and Experimental Medicine, University Hospital of Messina, University Hospital "G. Martino", Via C. Valeria, 98125, Messina, Italy. catalanoa@unime.it. 2. Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. 3. Department of Clinical and Experimental Medicine, University Hospital of Messina, University Hospital "G. Martino", Via C. Valeria, 98125, Messina, Italy. 4. Department of Human Pathology, University of Messina, Messina, Italy. 5. Mineral Metabolism and Nephrology Clinic of Vibo Valentia Hospital, Vibo Valentia, Italy.
Abstract
PURPOSE: Denosumab has been proven to reduce fracture risk in breast cancer (BC) women under aromatase inhibitors (AIs). Quantitative ultrasound (QUS) provides information on the structure and elastic properties of bone. Our aim was to assess bone health by phalangeal QUS and by dual-energy X-ray absorptiometry (DXA), and to evaluate bone turnover in AIs-treated BC women receiving denosumab. METHODS: 35 Postmenopausal BC women on AIs were recruited (mean age 61.2 ± 4.5 years) and treated with denosumab 60 mg administered subcutaneously every 6 months. Phalangeal QUS parameters [Amplitude Dependent Speed of Sound (AD-SoS), Ultrasound Bone Profile Index (UBPI), Bone Transmission Time (BTT)] and DXA at lumbar spine and femoral neck were performed. Serum C-telopeptide of type 1 collagen (CTX) and bone-specific alkaline phosphatase (BSAP) were also measured. The main outcomes were compared with a control group not receiving denosumab (n = 39). RESULTS: In patients treated with denosumab, differently from controls, QUS and DXA measurements improved after 24 months, and a reduction of CTX and BSAP was detected at 12 and 24 months in comparison to baseline (P < 0.05). The percent changes (Δ) of QUS measurements were significantly associated with ΔBMD at femoral neck, and ΔCTX and ΔBSAP were associated with ΔBMD at lumbar spine (r = -0.39, P = 0.02; r = -0.49, P = 0.01, respectively). CONCLUSIONS: Denosumab preserves bone health as assessed by phalangeal QUS and DXA. Since inexpensive and radiation-free, phalangeal QUS may be considered in the follow-up of AIs-treated BC women receiving denosumab.
PURPOSE:Denosumab has been proven to reduce fracture risk in breast cancer (BC) women under aromatase inhibitors (AIs). Quantitative ultrasound (QUS) provides information on the structure and elastic properties of bone. Our aim was to assess bone health by phalangeal QUS and by dual-energy X-ray absorptiometry (DXA), and to evaluate bone turnover in AIs-treated BC women receiving denosumab. METHODS: 35 Postmenopausal BC women on AIs were recruited (mean age 61.2 ± 4.5 years) and treated with denosumab 60 mg administered subcutaneously every 6 months. Phalangeal QUS parameters [Amplitude Dependent Speed of Sound (AD-SoS), Ultrasound Bone Profile Index (UBPI), Bone Transmission Time (BTT)] and DXA at lumbar spine and femoral neck were performed. Serum C-telopeptide of type 1 collagen (CTX) and bone-specific alkaline phosphatase (BSAP) were also measured. The main outcomes were compared with a control group not receiving denosumab (n = 39). RESULTS: In patients treated with denosumab, differently from controls, QUS and DXA measurements improved after 24 months, and a reduction of CTX and BSAP was detected at 12 and 24 months in comparison to baseline (P < 0.05). The percent changes (Δ) of QUS measurements were significantly associated with ΔBMD at femoral neck, and ΔCTX and ΔBSAP were associated with ΔBMD at lumbar spine (r = -0.39, P = 0.02; r = -0.49, P = 0.01, respectively). CONCLUSIONS:Denosumab preserves bone health as assessed by phalangeal QUS and DXA. Since inexpensive and radiation-free, phalangeal QUS may be considered in the follow-up of AIs-treated BC women receiving denosumab.
Entities:
Keywords:
Aromatase inhibitors; Bone mineral density; Bone turnover; Breast cancer; Denosumab; Quantitative ultrasound
Authors: Eric Orwoll; Christence S Teglbjærg; Bente L Langdahl; Roland Chapurlat; Edward Czerwinski; David L Kendler; Jean-Yves Reginster; Alan Kivitz; E Michael Lewiecki; Paul D Miller; Michael A Bolognese; Michael R McClung; Henry G Bone; Östen Ljunggren; Bo Abrahamsen; Ugis Gruntmanis; Yu-Ching Yang; Rachel B Wagman; Suresh Siddhanti; Andreas Grauer; Jesse W Hall; Steven Boonen Journal: J Clin Endocrinol Metab Date: 2012-06-21 Impact factor: 5.958
Authors: Angela M Cheung; Lianne Tile; Savannah Cardew; Sandhya Pruthi; John Robbins; George Tomlinson; Moira K Kapral; Sundeep Khosla; Sharmila Majumdar; Marta Erlandson; Judy Scher; Hanxian Hu; Alice Demaras; Lavina Lickley; Louise Bordeleau; Christine Elser; James Ingle; Harriet Richardson; Paul E Goss Journal: Lancet Oncol Date: 2012-02-07 Impact factor: 41.316
Authors: Michael Gnant; Georg Pfeiler; Peter C Dubsky; Michael Hubalek; Richard Greil; Raimund Jakesz; Viktor Wette; Marija Balic; Ferdinand Haslbauer; Elisabeth Melbinger; Vesna Bjelic-Radisic; Silvia Artner-Matuschek; Florian Fitzal; Christian Marth; Paul Sevelda; Brigitte Mlineritsch; Günther G Steger; Diether Manfreda; Ruth Exner; Daniel Egle; Jonas Bergh; Franz Kainberger; Susan Talbot; Douglas Warner; Christian Fesl; Christian F Singer Journal: Lancet Date: 2015-05-31 Impact factor: 79.321
Authors: Claus C Glüer; Richard Eastell; David M Reid; Dieter Felsenberg; Christian Roux; Reinhard Barkmann; Wolfram Timm; Tilo Blenk; Gabi Armbrecht; Alison Stewart; Jackie Clowes; Friederike E Thomasius; Sami Kolta Journal: J Bone Miner Res Date: 2004-03-01 Impact factor: 6.741
Authors: A Gaudio; R Rapisarda; A Xourafa; L Zanoli; V Manfrè; A Catalano; S S Signorelli; P Castellino Journal: J Endocrinol Invest Date: 2021-03-06 Impact factor: 5.467